Literature DB >> 9631661

Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins.

R E Hileman1, J R Fromm, J M Weiler, R J Linhardt.   

Abstract

Although interactions of proteins with glycosaminoglycans (GAGs), such as heparin and heparan sulphate, are of great biological importance, structural requirements for protein-GAG binding have not been well-characterised. Ionic interactions are important in promoting protein-GAG binding. Polyelectrolyte theory suggests that much of the free energy of binding comes from entropically favourable release of cations from GAG chains. Despite their identical charges, arginine residues bind more tightly to GAGs than lysine residues. The spacing of these residues may determine protein-GAG affinity and specificity. Consensus sequences such as XBBBXXBX, XBBXBX and a critical 20 A spacing of basic residues are found in some protein sites that bind GAG. A new consensus sequence TXXBXXTBXXXTBB is described, where turns bring basic interacting amino acid residues into proximity. Clearly, protein-GAG interactions play a prominent role in cell-cell interaction and cell growth. Pathogens including virus particles might target GAG-binding sites in envelope proteins leading to infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9631661     DOI: 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.0.CO;2-R

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  188 in total

1.  Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation.

Authors:  A P Byrnes; D E Griffin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Characterization of Sp17: a ubiquitous three domain protein that binds heparin.

Authors:  Y Wen; R T Richardson; E E Widgren; M G O'Rand
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

3.  Heparan sulfate proteoglycans are ligands for receptor protein tyrosine phosphatase sigma.

Authors:  A Radu Aricescu; Iain W McKinnell; Willi Halfter; Andrew W Stoker
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

4.  Control of Dpp morphogen signalling by a secreted feedback regulator.

Authors:  Robin Vuilleumier; Alexander Springhorn; Lucy Patterson; Stefanie Koidl; Matthias Hammerschmidt; Markus Affolter; George Pyrowolakis
Journal:  Nat Cell Biol       Date:  2010-05-09       Impact factor: 28.824

5.  Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo.

Authors:  C W Mandl; H Kroschewski; S L Allison; R Kofler; H Holzmann; T Meixner; F X Heinz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

6.  Bartonella henselae Pap31, an extracellular matrix adhesin, binds the fibronectin repeat III13 module.

Authors:  S M Dabo; A W Confer; B E Anderson; Snehalata Gupta
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

7.  Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1.

Authors:  Sharmila Raman; Tien-Huei Hsu; Shanna L Ashley; Katherine R Spindler
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

8.  Identification of the receptor binding domain of the mouse mammary tumor virus envelope protein.

Authors:  Yuanming Zhang; John C Rassa; Maria Elena deObaldia; Lorraine M Albritton; Susan R Ross
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Identification of a heparin-binding motif on adeno-associated virus type 2 capsids.

Authors:  A Kern; K Schmidt; C Leder; O J Müller; C E Wobus; K Bettinger; C W Von der Lieth; J A King; J A Kleinschmidt
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor.

Authors:  Chee Wah Tan; Chit Laa Poh; I-Ching Sam; Yoke Fun Chan
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.